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Abstract
Clinical trials using strategies aimed at inducing dystrophin expression in Duchenne muscu-
lar dystrophy (DMD) are underway or at advanced planning stage, including splice switching
antisense oligonucleotides (AON), drugs to induce read-through of nonsense mutations and
viral mediated gene therapy. In all these strategies, different dystrophin proteins, often inter-
nally deleted, are produced, similar to those found in patients with the milder DMD allelic var-
iant, Becker muscular dystrophy (BMD). The primary biological endpoint of these trials is to
induce functional dystrophin expression. A reliable and reproducible method for quantifica-
tion of dystrophin protein expression at the sarcolemma is crucial to monitor the biochemical
outcome of such treatments. We developed a new high throughput semi quantitative fluo-
rescent immunofluorescence method for quantifying dystrophin expression in transverse
sections of skeletal muscle. This technique is completely operator independent as it based
on an automated scanning system and an image processing script developed with Definiens
software. We applied this new acquisition-analysis method to quantify dystrophin and sarco-
lemma-related proteins using paediatric control muscles from cases without a neuromuscu-
lar disorder as well as DMD and BMD samples. The image analysis script was instructed to
recognize myofibres immunostained for spectrin or laminin while dystrophin was quantified
in each identified myofibre (from 2,000 to over 20,000 fibres, depending on the size of the
biopsy). We were able to simultaneously extrapolate relevant parameters such as mean sar-
colemmal dystrophin, mean spectrin and laminin intensity, fibre area and diameter. In this
way we assessed dystrophin production in each muscle fibre in samples of DMD, BMD and
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Introduction
Duchenne muscular dystrophy (DMD, MIM 310200) is a severe form of muscular dystrophy
caused by mutations in the dystrophin gene (DMD) that leads to a lack of dystrophin protein
production, and results in muscle degeneration and premature death of the patients (reviewed
in [1]). This X-linked condition affects approximately 1/5,000 male births worldwide [2].
Genetic aberrations (nonsense mutations, exons duplication and exons deletions) interrupt
the open reading frame and abolish dystrophin protein production. In order to induce dystro-
phin protein expression, many different approaches are being tested. These include: i) delivery
of functional mini- and micro-dystrophins by recombinant adeno-associated viral (rAAV)
vectors [3] ii) therapeutic exon skipping using antisense oligonucleotides (AON) [4]; iii) drugs
to induce read through of nonsense mutations [5]; iv) stem cell-mediated approaches [6] and
CRISPR-Cas9 genome editing strategies [7]. The most advanced of these approaches relates to
the use of AONs which induce exon skipping and restore the transcript reading frame, dis-
rupted in DMD cases carrying out of frame deletions. AONs eventually promote the transla-
tion of an internally deleted dystrophin protein, mimicking what occurs in the milder allelic
condition Becker muscular dystrophy (BMD). This should prevent or delay muscle fibre
degeneration and ameliorate disease progression [1]. As the primary biological endpoint of
these DMD clinical trials is the production of functional dystrophin, it is crucial to have a reli-
able and reproducible method for dystrophin quantification. While a number of methodolo-
gies ranging from semi-quantitative western blot [8] to mass spectrometry [9] have been
developed to accurately measure dystrophin in muscle lysates, a limitation of these techniques
is that they do not allow the assessment of the proper localization of dystrophin at sarcolemma.
As the main function of dystrophin is to stabilize a number of proteins of the dystrophin asso-
ciated glycoprotein complex at the sarcolemma [10], it is crucial to know that dystrophin is
correctly localized and consequently able to exert its mechanical reinforcement during muscle
contraction [11]. Our group was the first to publish a detailed immunohistochemistry protocol
for quantifying dystrophin expression [12]. This method exploited dystrophin and spectrin
immunofluorescence quantification and is based on single labelling performed on serial trans-
verse sections of a muscle biopsy. For each muscle sample, 40 regions of interest were analyzed
by capturing sarcolemmal labelling membrane intensity and dystrophin quantification was
expressed as an arbitrary intensity measure of dystrophin/spectrin signal ratios. We demon-
strated that this analysis was reproducible across different laboratories [8] and we used it for
quantifying dystrophin after AON administration in DMD patients enrolled in two clinical tri-
als [13, 14]. However, this method is extremely time consuming and also depends on a skilled
operator; for these reasons it is not suitable for analyzing large numbers of samples and is
potentially prone to operator bias. Another image analysis method is based on a double label-
ling, where dystrophin and spectrin are simultaneously detected [15]. The authors created an
image processing script in Metamorph software which exploited the spectrin signal for recog-
nizing fibres and generated a computational mask of sarcolemma areas where dystrophin was
quantified and expressed as average intensity. This method was based on confocal images
acquired randomly and gave a representative quantification of dystrophin expression [15].
A novel immunofluorescence method for quantifying dystrophin intensity
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Another conceptually similar method, developed by Beekman and collaborators, is also based
on a double labelling and confocal acquisition using Definiens software and allowed the evalu-
ation of dystrophin expression in each individual fibre in representative confocal image series
[16]. This method was a major step forward in dystrophin quantification, but also has some
limitations as dystrophin could be quantified only in a subset of fibres; indeed only ~ 400 fibres
on average were analyzed per section. Nevertheless, after appropriate operator training, both
the Taylor and Beekman methods correlated well with the Arechavala method [8], but the con-
cerns related to the potential bias for the selection of the regions of interest remained, espe-
cially in the context of clinical trials in which dystrophin restoration is one of the outcome
measures. Herein, we have developed a new acquisition-analysis method that is able to
capture all the intact fibres present in the muscle sections. This new analysis system is operator
independent because it is based on an automated scanner and an image processing script.
Furthermore, the computing analysis was instructed to simultaneously extrapolate multiple
parameters for each individual fibre such as sarcolemmal and cytoplasmic dystrophin intensity
expression, cytoplasmic and sarcolemmal spectrin or laminin intensity expression, number of
fibres and area of sarcolemmal and cytoplasmic compartments. We demonstrate that this
innovative technique gives reproducible results that extend the applicability and reproducibil-
ity of previous methods [12] [15] [16].
Materials and methods
Ethics statement
Skeletal muscle biopsies were obtained from the MRC Centre for Neuromuscular Diseases
Biobank London (REC reference number: 14/SC/1128). This study was performed under
approval by the NHS National Research Ethics Committee (REC reference number: 05/
MRE12/32). Parents or legal guardians of children gave written informed consent.
Muscle biopsies
Fresh muscle biopsies were placed on cork support, mounted with OCT (Agar Scientific, UK)
and subsequently frozen in isopentane cooled in liquid nitrogen following standard proce-
dures (Dubowitz V, Sewry C, Oldfors A. Muscle biopsy: a practical approach. 4th ed. Elsevier-
Saunders; 2013). Open muscle biopsies from the quadriceps were obtained from molecularly
confirmed patients with DMD or BMD. We also obtained control muscle biopsies from paedi-
atric patients (age range from 3 to 13 years old as reported in Table 1) who underwent ortho-
paedic surgery and in whom a primary neuromuscular disease was excluded after extensive
clinical and laboratory evaluation (henceforth referred to as ‘controls’). These control muscle
biopsies were from quadriceps (sometimes vastus lateralis), gastrocnemius, peroneous longus,
and abductor halluces/quadratus plantae muscles of the foot (Table 1) depending on the type
of surgery. For some of them (control 3, 4 and 6), the size of the specimen was sufficient to
generate two OCT blocks.
Sectioning and immunofluorescence labelling
Serial unfixed frozen transverse sections (7μm) were cut with a Leica 1850 CM cryostat
(LEICA Microsystem, Milton Keynes, UK). Each slide carried two muscle sections to perform
each experiment in duplicate. Slides were removed from the freezer and air dried for 20 min-
utes before staining.
Single labelling. Single immunolabelling was performed with rabbit polyclonal anti-dys-
trophin ab15277 (1:200, Abcam, Cambridge, UK), mouse monoclonal anti-dystrophin
A novel immunofluorescence method for quantifying dystrophin intensity
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MANDYS106 (1:100, gift from Prof. Glen Morris and is now commercially available
(MABT827, clone 2C6, Millipore), mouse monoclonal anti-spectrin (1:20, Leica Microsystem,
Milton Keynes, UK) and rat monoclonal anti-laminin α-2 (4H8-2, 1:50, Enzo Life Science,
Exeter, UK, subsequently referred as anti-laminin) antibodies. Muscle sections were incubated
for 1 hour at room temperature (RT) with the primary antibodies followed by secondary bioti-
nylated IgG antibodies raised against the matched species for 30 minutes (1:200; anti rabbit
IgG or anti mouse IgG, GE Healthcare, Amersham Pl, UK). Sections were finally incubated for
15 minutes with 594 Alexa Fluor anti-streptavidin (1:1000, Thermo Fisher Scientific, Hemel
Hempstead, UK). Between each incubation, three washes with phosphate buffered saline
(PBS 1X, Sigma Aldrich, Dorset, UK) of three minutes each were performed. Sections were
mounted using Hydromount (National Diagnostics, UK).
Double labelling. Two double labellings with two different combinations, depending on
the antibody species compatibility, were performed. The first combination was rabbit anti-dys-
trophin ab15277 (1:200, Abcam, Cambridge, UK) coupled with mouse anti-spectrin (1:20,
Novocastra, Milton Keynes, UK). The second combination used mouse anti-dystrophin
MANDYS106 (1:100, gift from Prof. Glen Morris) paired with rat anti-laminin (1:50, Enzo
Life Science, Exeter, UK). All the labellings were performed at RT. Muscle sections were incu-
bated with the primary antibody combination (anti-dystrophin ab15277 and anti-spectrin) for
1 hour. After three washes with PBS sections were incubated with Alexa Fluor 488 conjugated
anti-mouse IgG (1:100, Thermo Fisher Scientific, Hemel Hempstead, UK) and anti-rabbit bio-
tinylated IgG (1:200; GE Healthcare, Amersham Pl, UK) for 30 minutes. PBS washes were per-
formed and sections were incubated with Alexa Fluor 594 streptavidin conjugate (1:1000,
Thermo Fisher Scientific, Hemel Hempstead, UK). For performing the second antibody com-
bination (anti-dystrophin MANDYS106 and anti-laminin) muscle sections were incubated
with the primary antibodies for 1 hour, then washed three times with PBS and incubated with
Alexa Fluor 488 conjugated anti-rat IgG (1:100, Thermo Fisher Scientific, Hemel Hempstead,
UK) and anti-mouse biotinylated IgG (1:200; GE Healthcare, Amersham Pl, UK) for 30 min-
utes. PBS washes were performed and sections were incubated for 15 minutes with Alexa
Fluor 594 streptavidin conjugate (1:1000, Thermo Fisher Scientific, Hemel Hempstead, UK).
Sections were mounted using Hydromount (National Diagnostic, UK). Further details of anti-
bodies and a schematic staining procedure are given in Table 2.
Table 1. Control, BMD and DMD muscle biopsies.
Patients Muscle group Age at the biopsy
(years)
Dystrophin mutation Functional motor score
(HMAS)
Age at the assessment
(years)
Control 1 Thigh 13 N/A N/A N/A
Control 2 Quadriceps 8 N/A N/A N/A
Control 3 Vastus lateralis 7 N/A N/A N/A
Control 4 Gastrocnemius 9 N/A N/A N/A
Control 5 Abductor hallucis/ quadratus plantae 16 N/A N/A N/A
Control 6 Peroneus longus 3 N/A N/A N/A
Control 7 Vastus lateralis 7 N/A N/A N/A
DMD 1 Quadriceps 4 c.583 C>T ex7 32/40 4
DMD 2 Quadriceps 8 c.9851 G>A ex 68 23/40 8
BMD 1 Quadriceps 7 Del exon 13 39/40 13
BMD 2 Vastus lateralis 3 Del exon 43–47 36/40 6
Functional motor score was assessed by performing the Hammersmith motor ability scale (HMAS) (Scott et al., 2012).
DMD, Duchenne muscular dystrophy; BMD, Becker muscular dystrophy; N/A, not applicable; NS, not specified.
https://doi.org/10.1371/journal.pone.0194540.t001
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Image acquisition
Images from serial sections cut and labelled at the same time were acquired with two different
protocols. The first protocol (fluorescent microscope) based on [12], allowed the capturing of
only a small area, while by performing the second protocol, using a slide scanner (Axio Scan.
Z1 slides scanner), the entire section was captured.
Fluorescent microscope. Immunolabelled sections were acquired using a Leica DMR
microscope (LEICA Microsystem, Milton Keynes, UK) interfaced to Metamorph (Molecular
Devices, Downingtown, PA, USA). Images were acquired using the 12-bit Photometrics Cool-
SnapHQ2 camera (LEICA Microsystems, Milton Keynes, UK) which has a dynamic range
between 0 and 4095 intensity units and images were acquired below the saturation limits. The
acquisition procedure followed the previously published protocol [12] where excitation times
for each fluorophore were established on the muscle sections obtained from two paediatric
controls. The average of the controls’ exposure times was used to acquire each patient section.
Four different images were acquired for each sample and subsequently analysed with the Meta-
morph software.
Axio Scan.Z1 slides scanner. Sections were scanned by the Axio Scan.Z1 slide scanner
(Zeiss, Germany) equipped with a Colibri illumination system and an Orca Flash 4.0 V2 cam-
era. For each fluorophore, exposure settings were established on sections of two paediatric
controls and the average value was used to acquire patients’ sections. Scanned images were
stored on a fileserver viewed and managed on the SlidePath Digital Image Hub (LEICA Micro-
system, Milton Keynes, UK). Analysis was carried out with an in house script developed in
Definiens Architect software (version 6.0, Definiens, Munich, Germany).
Image processing
Metamorph software. From each image acquired with Metamorph software interface, 10
different regions of interest (ROI) were randomly selected and intensity measurements were
assessed resulting in a total of 40 fibres analysed per sample. ROI intensity measurements
Table 2. Antibodies used on muscle sections.
Double-staining combinations
Anti-dystrophin ab15277 and spectrin Anti-dystrophin MANDYS106 and laminin Incubation time











Fibre identification primary antibody Mouse spectrin IgG2b
(Novocastra NCL-SPEC1)
1:20
Rat laminin-2 (α-2-chain) IgG1 (4H8-2)
(Enzo Life Science ALX-804-190-C100)
1:50
Secondary antibody Donkey anti-rabbit biotinylated IgG
(GE Healthcare RPN1004V)
1:200




Donkey anti-mouse IgG AlexaFluor 488
(Life Technologies A21202)
1:100
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included portion of the sarcolemma (maximum intensity) and portion of the cytoplasm (mini-
mum intensity).
Definiens in house script. Entire muscle sections were acquired by the Axio Scan.Z1 slide
scanner and images were processed in Definens Architect software. We developed a custom-
ised algorithm able to simultaneously extract multiple parameters such as dystrophin intensity,
fibre diameter and fibre size. The algorithm was instructed to only recognize extrafusal myofi-
bres exploiting the spectrin or laminin labelling and created a digital mask where dystrophin
was subsequently quantified in each individual myofibre (Fig 1). Depending on the size of the
muscle biopsy and the resulting cross sectional area, the script was able to identify from 1,000
to over 20,000 fibres within one section. Few muscle fibres had disruptions in either spectrin
or laminin staining. The algorithm was instructed to reconstruct fibre sarcolemma if the dis-
ruption was less than 20% of the entire fibre rim. We thus excluded from our analysis fibres
missing more than 20% of the fibre rim, assumining that such fibres were either severely dam-
aged or degenerating. Dystrophin mean intensity was assessed by the script using either the
dystrophin (ab15277 antibody)/spectrin combination, or the dystrophin (MANDYS106 anti-
body)/laminin combination. Dystrophin signal was expressed in arbitrary units (au) and plot-
ted as absolute fibre count (%) or as cumulative fibre count (%).
Fig 1. Algorithm development for identifying myofibres. Spectrin or laminin allow fibre identification within the muscle section. The algorithm was
instructed to recognize the tissue within the image (a) and to subsequently recognize the myofibres within the section (b). The algorithm then generated
a mask considering only structures presenting fibre characteristics (i.e. excluding nerves, spindles, blood cells, folded muscle tissue and connective areas
(c). The mask generated by the algorithm included only the sarcolemma compartment of myofibres and clearly defined fibre rims (d).
https://doi.org/10.1371/journal.pone.0194540.g001
A novel immunofluorescence method for quantifying dystrophin intensity
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The time taken to perform the analysis of each section is dependent on the size of the mus-
cle section and the corresponding size of the image files. Image acquisition takes 15–30 min-
utes and data acquisition 30 minutes- 1 hour/section (i.e. a total of 45 minutes– 1 hour 30
minutes/section). But these processes are automated and operator independent, guaranteeing
an unbiased data set. The operator time is mainly taken up by the analysis of the raw data
extrapolated by the Definiens algorithm.
Staining reproducibility and stability
In order to assess the reproducibility of the technique and protein stability, we assessed dystro-
phin expression within the same patient’s muscle biopsy in two separate experiments. We used
muscle blocks of two controls (control 1 and 2, Table 1). Two sets of serial transverse sections
were cut and labelled. The first set of labelled sections was acquired immediately. The second
set was stored at 4˚C and images were acquired after three months to evaluate if the dystrophin
fluorescent signal could decay across time.
Data analysis
Scatter dot plots represented data dispersion for dystrophin quantification. The mean ± standard
error of the mean (SEM) is represented for each normally-distributed data. A t-test or one way
ANOVA was used to determine differences between groups. The Mann Whitney test was used
for post hoc comparison. Statistical analysis was performed using GraphPad Prism version 6.07
(GraphPad Software, La Jolla, CA) and significance levels were set as: , p<0.05; , p<0.01
and , p< 0.001. The coefficient of variation (CV) was calculated to assess biological variability
wherever indicated. CV was calculated using the formula CV = (standard deviation (DS) /
mean) X 100.
Results
Development of a new high-throughput semi-automated acquisition
method for identifying all muscle fibres within a transverse section
The customised algorithm developed in Definiens Architect software allowed us to recognize
the majority of myofibres (99.8%) present within a muscle section and to calculate dystrophin
mean intensity for each individual fibre. This algorithm recognized only extrafusal muscle
fibres and excluded other structures present in the muscle section (such as fibrotic or necrotic
areas, blood cells, vessels, nerves, spindles, adipose and connective tissue). During the algo-
rithm development, a visual inspection of unmodified digital images was performed by one
operator (M.E.) to check that the script was able to correctly identify the total number of myo-
fibres present within the muscle section. Two different dystrophin antibodies were studied in
parallel experiments: anti-dystrophin ab15277 which recognises the C-terminus of the protein
and specifically an epitope in exon 77 and anti-dystrophin MANDYS106, that recognizes the
protein epitope encoded by exon 43. Dystrophin quantification required myofibre identifica-
tion using either spectrin when dystrophin ab15277 antibody was used, or laminin for anti-
dystrophin MANDYS106. The algorithm development is summarised in Fig 1 and includes
the following steps: 1) spectrin or laminin staining used independently to identify structures
within the section (Fig 1a); 2) after structure identification, the algorithm generates a mask
that considers only structures with myofibre characteristics (Fig 1b and 1c) (methodological
paper under preparation, Ellis M. et al., 2017); 3) after fibre identification, the algorithm specif-
ically recognised the sarcolemma compartment and clearly defined fibre peripheries (Fig 1d).
A novel immunofluorescence method for quantifying dystrophin intensity
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The most crucial step in the algorithm was a precise fibre identification step. To do this, we
performed double labellings with either anti-spectrin or anti-laminin antibodies raised in dif-
ferent species compatible with the anti-dystrophin antibodies. Spectrin is generally used to
assess sarcolemma integrity since it is located just under the sarcolemma while laminin is
found in the basal lamina, outside the sarcolemma. Moreover, since the dystrophic pathology
can disrupt the sarcolemma and potentially affect the fibre recognition step, DMD muscle sec-
tions were analysed and more than 1,000 fibres/section visually inspected revealing that less
than 0.99% of fibres had interruptions in either the spectrin or laminin labelling. We found no
instances of the same fibre having both laminin and spectrin staining disrupted.
Spectrin, laminin and dystrophin mean intensity quantification with single
or double labelling in control muscles
To determine if each anti-dystrophin antibody could be used in combination with spectrin or
laminin without affecting the dystrophin signal intensity, we analysed mean dystrophin inten-
sity values obtained by single anti-dystrophin labelling compared to values recorded after dou-
ble labelling in serial muscle sections from two paediatric controls (control 1 and 2, Table 2).
Images of labelled sections were acquired and then analysed by Metamorph following the
method previously developed by us [12]. We found no significant variation in the mean dys-
trophin intensity when the labelling was performed using anti-dystrophin ab15277 alone or in
combination with anti-spectrin (Fig 2a). Similarly, when anti-dystrophin MANDYS106 was
used, there was no significant variation in the dystrophin mean intensity when the antibody
was used alone or in combination with anti-laminin (Fig 2b). Moreover, we found that spec-
trin and laminin signals had no variation in the mean intensity when the antibodies were used
Fig 2. Dystrophin and sarcolemma proteins intensities used in single and double labelling. Serial sections obtained
from two paediatric control muscles (control 1 and 2, Table 1) were used in single or double labelling. (Single labelling:
anti dystrophin ab15277, or anti dystrophin MANDYS106; double labelling: anti dystrophin ab15277 combined with
anti spectrin, or anti dystrophin MANDYS106 combined with anti laminin). For each staining, two sections were
stained simultaneously and four images were acquired per section using a fluorescent microscope and analysed by
Metamorph software following the Arechavala et al., 2010 method. Sarcolemma intensity values were plotted on the y
axis (Mean±SEM). Dystrophin intensity values plotted as dots are the difference between dystrophin intensity at the
sarcolemma and dystrophin intensity within the cytoplasm (considered to be background staining signal). Analyses
were performed using anti-dystrophin ab15277 (a), anti-dystrophin MANDYS106 (b), anti-spectrin (c) and anti-
laminin (d).
https://doi.org/10.1371/journal.pone.0194540.g002
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either alone, or in combination with the species compatible anti-dystrophin antibody (Fig 2c
and 2d).
Mean spectrin and laminin intensity quantification in control muscles, in
DMD and BMD muscle samples
In the recent literature, dystrophin has been presented as normalised values to the sarcolem-
mal marker protein, spectrin [8, 12, 15]. We acquired entire muscle sections using the Axio
Scan slide scanner and analysed images with the Definiens script. We found significantly
higher spectrin levels, 2.65 and 1.64 fold respectively (p< 0.01) in the muscle sections of DMD
and BMD patients (Table 3) compared to the average spectrin values detected in the paediatric
control muscles (Fig 3a). We also found that there was a statistically significant (p< 0.01)
higher level of the laminin mean intensity in the DMD and BMD muscle samples of 1.25 and
1.12 fold respectively compared to the average laminin signal detected in the control muscle
sections (Fig 3b). These data suggest that using spectrin or laminin to normalise dystrophin
intensity values will lead to an underestimation of the levels of dystrophin at the sarcolemma
in dystrophinopathies.
Dystrophin expression in control muscles varies between different muscle
types
We performed the following double labellings on sections from the seven paediatric controls:
anti-dystrophin ab15277 paired with anti spectrin, or anti-dystrophin MANDYS106 coupled
with anti-laminin. Mean dystrophin intensity for each individual fibre identified in each mus-
cle section was quantified and dystrophin mean intensity for each muscle specimen as well as
the average value of the mean dystrophin intensity were calculated. Analysis of the control
samples revealed no statistically significant differences between the average value of dystrophin
intensity when either anti-dystrophin ab15277 or anti-dystrophin MANDYS106 was used.
The dystrophin average intensity value in all the control muscle blocks analysed was 7607±25
i.v. (average ±SEM) when the staining was performed with anti-dystrophin ab15277 and 7533
±9.41 i.v. when anti-dystrophin MANDYS1056 was used. When the average value of dystro-
phin mean intensity for each muscle sample analysed was compared, we observed variability
Table 3. Labelling variability in different biological replicates of controls.
Anti-dystrophin ab15277
Control 1 Control 2
Nr. fibres Max MD Min MD Ave MD %CV Nr. fibres Max MD Min MD Ave MD %CV
EXP.A 14559 40968 3879 18109 19 16234 36567 4729 18700 15
EXP.B 12447 49339 7287 23271 25 13212 41870 7238 16779 24
EXP.C 12924 8627 2148 4628 11 12016 22011 3769 10381 18
Anti-dystrophin MANDYS106
Control 1 Control 2
Nr. fibres Max MD Min MD Ave MD %CV Nr. fibres Max MD Min MD Ave MD %CV
EXP.A 13245 31749 3248 10572 29 15159 28271 5962 15185 17
EXP.B 9961 29958 7707 17049 16 13321 37643 4614 20892 15
EXP.C 13530 5991 1785 3226 13 14878 16242 3342 6104 18
Muscle sections were cut from two muscle biopsies of non-neuromuscular donors and immediately stained and acquired (experiment A and experiment B). Sections
were cut, stained and stored for three months and subsequently acquired in experiment C. Max MD, Maximum Mean Dystrophin; Min MD, Minimum Mean
Dystrophy; Ave MD, Average Mean Dystrophin; CV, Coefficent Variation.
https://doi.org/10.1371/journal.pone.0194540.t003
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depending on which type of muscle was analysed. Dystrophin labelling performed with both
anti-dystrophin antibodies ab15277 and MANDYS106 gave the highest dystrophin average
intensity in a quadriceps muscle (control 2, 18700±23 and 15185±22 i.v. respectively) while the
lowest dystrophin average intensity was obtained in a peroneous longus muscle (control 6,
3670±11 and 5041±6 i.v. respectively). We found no significant variations in the mean
dystrophin intensity between sections obtained from the two muscle blocks derived from the
same muscle biopsy in any of these three non-neuromuscular donors (control 3, 4 and 6, Fig
4a and 4b).
Dystrophin expression in control muscles varies between different
independent experiments
We then compared dystrophin expression in sections scanned immediately after staining (Fig
5, EXP A) and after the two muscle blocks were kept at -80˚C for one month and sections were
cut again, stained and images acquired in the same way as before (Fig 5, EXP B). There were
Fig 3. Spectrin and laminin mean intensity in muscle sections of DMD, BMD and control patients. Muscle
sections were cut from two paediatric controls, two DMD and two BMD patients. Two biological replicate experiments
were performed and for each experiment two sections per sample were stained with anti-spectrin or anti-laminin and
acquired by the Axio Scan slide scanner. The Definens script extrapolated spectrin or laminin intensities for each
individual myofibre identified within the section. Protein intensities data for spectrin (a) or for laminin (b) were
grouped per category (CTR, DMD and BMD) as mean±SEM. The Mann Whitney test revealed significant differences
between CTR, DMD and BMD for both spectrin (a) and laminin (b) fluorescent intensities (, p<0.001). (CTR:
control; DMD: Duchenne muscular dystrophy; BMD: Becker muscular dystrophy; SEM: standard error of the mean).
https://doi.org/10.1371/journal.pone.0194540.g003
Fig 4. Dystrophin expression in different muscle types obtained from paediatric controls. Ten muscle blocks
derived from different muscle groups obtained from seven controls (Table 1) were analysed performing anti-
dystrophin ab15277/anti-spectrin and anti-dystrophin MANDYS106/anti-laminin stainings. Entire muscle sections
were acquired by the Axio Scan slide scanner and processed by the Definiens algorithm, exploiting spectrin or laminin
staining for fibre identification. Dystrophin was quantified in each individual fibre using either anti-dystrophin
ab15277 (Fig 4a) or MANDYS106 (Fig 4b) intensities plotted as arbitrary units. We acquired a different number of
myofibres (22,000 fibres for control 3 to 5,000 fibres for control 5) per section depending on the cross sectional area.
https://doi.org/10.1371/journal.pone.0194540.g004
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statistically significant (p<0.01) different mean dystrophin intensity values in the two inde-
pendent experiments in which muscle sections were cut, stained and acquired immediately
(EXP A and B) when either anti-dystrophin ab15277 (Fig 5a) or anti-dystrophin MANDYS106
were used (Fig 5b). Coefficient variations (CV) calculated on sections obtained from two pae-
diatric controls and stained with anti-dystrophin ab15277 varied from 19 to 25% for control 1
and from 15 to 24% for control 2 (Table 3, EXP A and B). Also by using MANDYS106 we
observed variable levels between the two independent biological replicates: for control 1, we
detected a %CV from 16 to 29% and from 15 to 17% for control 2. We also investigated
whether the dystrophin intensity signal was affected if the image acquisition was not per-
formed immediately after staining. To do this, sections were cut, stained and images acquired
after been kept for three months at 4˚C (Fig 5, EXP C). As expected after such a long storage
time, a significant decrease in the dystrophin mean intensity levels was observed when the
acquisition was performed three months after the staining than from serial sections in which
images were acquired immediately after staining. When sections from controls were stained
with ab15277, there was a reduction of 78% (for control 1) and 51% (for control 2) of dystro-
phin mean intensity in stained sections that had been stored for 3 months before acquisition
compared to dystrophin levels observed when acquisition was performed immediately after
staining (mean dystrophin value calculated by averaging EXP A and B). For sections stained
with MANDYS106, there was a reduction of dystrophin mean intensity of 87% (for control 1)
and 33% (for control 2) in stained sections that had been stored for 3 months before acquisi-
tion compared to the dystrophin levels obtained immediately after staining (Table 3).
The dynamic range of dystrophin intensity and the different dystrophin
average intensities when using Metamorph method
Dystrophin quantification performed by the Metamorph method [12] gave intensity values
(i.v.) in a different dynamic range from the Axio Scan-Definiens method described above.
Anti-dystrophin ab15277.
• Dynamic range
With this antibody, the highest dystrophin intensity values (i.v) for controls 1 and 2 were
around 3,700, 3,193 (BMD 1), 2,611 (BMD 2), 691 (DMD 1) and 394 (DMD 2). The lowest
Fig 5. Variability in dystrophin quantification in independent immunostaining and dystrophin signal detection
stability across the time. Double staining with different antibody combinations were performed (anti-dystrophin
ab15277/anti spectrin (a) and anti-dystrophin MANDYS106/anti-laminin (b)). Sections were cut and stained
immediately (A). Muscle blocks were kept at -80˚C for one month and then two section sets were cut and again stained
immediately. One set of these stained sections were acquired immediately (B) whereas the other stained section set was
kept at 4˚C for three months and then acquired (C) in order to evaluate the fluorescent signal stability of dystrophin
staining after slides long time storage. Dystrophin intensities were quantified per each individual fibre and were
plotted as scatter plots (mean±SEM) in arbitrary units (p< 0.001, Mann Whitney test). Dystrophin intensity
dynamic range and number of fibres acquired per experiment are reported in Table 3.
https://doi.org/10.1371/journal.pone.0194540.g005
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dystrophin intensities were 590 (control 1) and 292 (control 2), 594 (BMD 1) and 252 (BMD
2), 85 (DMD 1) and 45 (DMD 2) (Fig 6).
• Average
The average dystrophin i.v. were 1,718 (control 1), 1,506 (control 2), 1,619 (BMD 1), 1,048
(BMD 2), 250 (DMD 1) and 139 (DMD 2) (Fig 6).
Anti-dystrophin MANDYS106.
• Dynamic range
The highest dystrophin i.v. were 3,591 (control 1), 3,803 (control 2), 3,803 (BMD 1), 1,588
(BMD 2), 922 (DMD 1) and 453 (DMD 2). The lowest values were 353 (control 1), 581 (con-
trol 2), 605 (BMD 1), 339 (BMD 2), 80 (DMD 1) and 69 (DMD 2) (Fig 6).
• Average
The dystrophin intensity averages were 1,613 (control 1), 1,440 (control 2), 1,917 (BMD 1),
873 (BMD 2), 80 (DMD 1) and 69 (DMD 2), similar to the average intensities with anti-dystro-
phin ab15277 (Fig 6).
Dystrophin mean intensity varies in the myofibre populations identified within the
entire muscle sections of DMD and BMD patients and controls after Axio Scan-Definiens
analysis.
We observed that dystrophin is differentially expressed among individual fibres recognised
within each section. There was variability in control sections as well as in both DMD and
Fig 6. Dystrophin intensities quantification by the Arechavala et al., 2010 method using two different anti-
dystrophin antibodies. Serial sections were cut from muscle blocks of two controls (control 1 and 2), two DMD and
two BMD patients. Immunostainings were performed used two antibody combinations: 1) anti-dystrophin ab15277/
anti spectrin and 2) anti-dystrophin MANDYS106/anti laminin. For each staining procedure two serial sections were
stained as biological replicates Dystrophin intensities values recorded with anti-dystrophin ab15277 were plotted in
red, whereas data obtained with MANDYS106 were displayed as orange dots. Data plots as scatter dots with
mean ± SEM. CTR: control; DMD: Duchenne muscular dystrophy; BMD: Becker muscular dystrophy; SEM: standard
error of the mean.
https://doi.org/10.1371/journal.pone.0194540.g006
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Fig 7. Dystrophin quantification in a population of myofibres identified in entire muscle sections performing the double labelling anti-
dystrophin ab15277 and anti-spectrin. Representative images of entire muscle sections stained and acquired by the Axio Scan slide scanner and
processed with Definens algorithm derived from a control (a) and from a DMD patient (b). Graph of representative dystrophin quantification in the
fibre population of a control, a DMD and a BMD muscle sample (c). Dystrophin quantification was plotted as cumulative fibre count (%) on the
primary y axis. The blue dashed line represents the dystrophin intensity distribution of a representative control sample (control 1, Table 1), the green
dashed line represents the BMD sample and the DMD sample is represented by the red dashed line. The distribution curve of the absolute dystrophin
fibre count for the control sample is represented by the blue peak, for the BMD is expressed by the green peak and the DMD fibre population curve is
represented by the red peak. Fibres analysed in this representative muscle sections were: ~ 14500 for the control, ~ 10000 for the BMD and ~ 2700 for
the DMD muscle section.
DMD: Duchenne Muscular Dystrophy; BMD: Becker Muscular Dystrophy; i.v: intensity values.
https://doi.org/10.1371/journal.pone.0194540.g007
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Fig 8. Dystrophin quantification in a population of myofibres identified in an entire muscle sections performing the double labelling anti-
dystrophin MANDYS106 and anti-laminin. Representative images of entire muscle sections stained and acquired by the Axio Scan slide scanner
and processed with Definiens algorithm derived from a control (a) and from a DMD patient (b). Representative dystrophin quantification in
population of fibres of control, DMD and BMD muscle samples (c). Blue dashed line represents the dystrophin intensity distribution of a
representative control sample (control 1, Table 1). Dystrophin absolute count obtained from the BMD sample (BMD 1, Table 1) is represented by
A novel immunofluorescence method for quantifying dystrophin intensity
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BMD patient sections, (Figs 7c and 8c) but the degree of variability was different. Dystrophin
quantification data was plotted as dystrophin absolute count (%) represented by normally-dis-
tributed curves and as dystrophin cumulative fibre count (%) represented by frequency distri-
bution curves (Figs 7c and 8c).
• Controls
Cross-sectional areas of the sections from the control muscles contained more than 10,000
fibres similar to sections of the two BMD samples (Table 4). The dynamic range of dystro-
phin mean intensity varied from 3879 to 49,399 i.v. when sections were stained with anti-
dystrophin ab15277 (Table 4). The fibres had an average dystrophin intensity of approxi-
mately 19,000 i.v. (Table 4) and the related distribution curve of the absolute fibre count
is represented by a wider peak, similar to that observed in BMD patients (Fig 7c). Control
sections stained with anti-dystrophin ab15277 had a heterogeneous myofibre population
expressing different levels of mean dystrophin intensity, as demonstrated by the wide
dynamic range and the wide peak. Similar results were obtained using the anti-dystrophin
MANDYS106 antibody (Fig 8c). Analysis of the absolute fibre count demonstrates that even
for the MANDYS106 staining, control muscle sections are represented by a population of
myofibres expressing different mean dystrophin intensities. After anti-dystrophin MAN-
DYS106 staining, the myofibre population had an average dystrophin intensity of around
16,000 i.v. (Table 4) with a dynamic range of 3,248 to 37,648 i.v. (Fig 8c).
the dark green dashed line whereas the related dystrophin intensity distribution of the DMD sample is represented by the pink dashed line. The
distribution curve of the absolute dystrophin fibre count for the control sample is represented by the blue peak, for the BMD sample is expressed in
dark green and the DMD sample is represented by the pink peak. Numbers of fibres analysed in these representative muscle sections were: ~ 1300
for the control, ~ 10000 for the BMD and ~ 2700 for the DMD muscle section.
DMD: Duchenne Muscular Dystrophy; BMD: Becker Muscular Dystrophy; i.v: intensity values.
https://doi.org/10.1371/journal.pone.0194540.g008
Table 4. Intensity dystrophin range in muscle sections of DMD/BMD patients and controls.
Dystrophin intensity ab15277
Experiment 1 Experiment 2
Sample Range values
(min;MAX)
Mean±SEM Nr.fibres/section CV % Range values
(min;MAX)
Mean±SEM Nr.fibres/section CV%
Control 1 3879;40968 18109±29.58 14559 19.71 7287;49399 23271±52.66 12447 25.24
Control 2 4729;36567 18700±23.29 16234 15.86 7238;41870 16779±35.88 13212 24.58
DMD 1 1837:15756 3978±20.38 2719 26.71 3518;10140 5417±20.19 1583 20.19
DMD 2 1521;6114 2413±12.99 1557 21.24 2939;11071 4759±29.63 1112 20.76
BMD 1 2243;33781 15926±33.22 10417 21.29 2286;32372 15529±35.11 9118 21.59
BMD 2 2843;21961 11063±18.43 10857 17.36 2915;45672 12032±19.99 13267 19.14
Dystrophin intensity MANDYS106
Experiment 1 Experiment 2
Sample Range values
(min;MAX)
Mean±SEM Nr.fibres/section CV % Range values
(min;MAX)
Mean±SEM Nr.fibres/section CV%
Control 1 3248;31749 10572±26.99 13245 29.37 7707;29958 17049±27.92 9961 16.34
Control 2 5962;28271 15185±22.06 15159 22.06 4614;37648 20882±28.26 13321 15.61
DMD 1 2025;8360 3632±14.75 2732 21.23 4150;14969 7038±43.77 1466 23.81
DMD 2 1898;5703 3391±15.22 1751 18.78 4101;7624 5621±19.26 1095 11.33
BMD 1 2582;33658 13419±38.02 9820 28.08 3984;37345 15589±37.13 9358 23.03
BMD 2 2599;21047 9352±20.27 10482 22.19 6158;30687 16433±37.87 7732 20.26
DMD, Duchenne muscular dystrophy; BMD, Becker muscular dystrophy; min, minimum intensity value; MAX, maximum intensity value, SEM, standard error of the
mean, %CV, % of coefficient variation.
https://doi.org/10.1371/journal.pone.0194540.t004
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• BMD
The number of myofibres (~ 10,000) present and correctly identified within BMD muscle
sections after the Axio Scan-Definiens method was similar to the number of myofibres iden-
tified in the control muscle sections (Table 4). The myofibres in the BMD samples had an
average dystrophin mean intensity of approximately 13,600 i.v. when anti-dystrophin
ab15277 was used (Table 4). The dynamic range of dystrophin mean intensity per fibre was
wider than in the DMD samples, with minimum and maximum values of 2,243 i.v. and
45,672 i.v., respectively. The broader expression is also clearly represented by a wider peak
for the absolute fibre count (Fig 7c). There was a similar pattern when BMD samples were
stained with MANDYS106, as the mean dystrophin intensity per fibre was represented by a
broader distribution curve of the absolute fibre count (Fig 8c). Even for MANDYS106, the
average of the dystrophin mean intensity in the overall myofibre population analysed in the
BMD muscles is around 13,600 i.v., similar to the value obtained when ab15277 was used.
The dynamic range of dystrophin mean intensity per fibre ranged from 2582 to 37,354 i.v.
(Fig 9 and Table 4).
• DMD
The mean dystrophin intensity using ab15277 antibody in DMD muscles varied from 1,521
to 15,756 i.v. (minimum-maximum values). Nevertheless, the fibres had mean dystrophin
intensity values similar to the average value calculated for the entire population of muscle
fibres (approximately 4,000 i.v.) (Table 4). Indeed, this finding is clearly illustrated by
observing the absolute fibre count graph, where the myofibre population is represented by a
narrow distribution curve (Fig 7c). DMD muscle sections stained with anti-dystrophin
MANDYS106 gave the same pattern of variable mean dystrophin intensity values. Using this
Fig 9. Dystrophin quantification after immunostaining with anti-dystrophin ab15277 or anti-dystrophin
MANDYS106 after Axio Scan-Definiens analysis. Serial muscle sections from two controls (control 1 and 2, Table 1),
two DMD and two BMD patients were cut and stained with the two antibody combinations (anti-dystrophin ab15277/
anti spectrin and anti-dystrophin MANDYS106/anti-laminin). Spectrin and laminin were used only to recognize the
fibres and dystrophin was quantified and expressed as absolute intensity with both ab15277 (red dots) and
MANDYS106 (orange dots). The number of myofibres per sample varies and are indicated in Table 4.
https://doi.org/10.1371/journal.pone.0194540.g009
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antibody, the dynamic range of dystrophin mean intensity is between 1,898 and 7,038 i.v.
with the fibres expressing a mean dystrophin intensity of about 4,700 i.v. (Table 4). The abso-
lute fibre count shows a narrow distribution curve similar to that observed using anti-dystro-
phin ab15277 (Fig 8c).
• Comparison of the myofibre populations identified in the DMD/BMD and control mus-
cle sections
We found that, as expected, myofibre populations in dystrophic muscles expressed a signifi-
cantly lower level of dystrophin compared to paediatric control muscles. Using anti-dystro-
phin ab15277, we found a reduction of 83% of dystrophin mean intensity in the two DMD
samples analysed compared to the dystrophin mean intensity levels in the two control mus-
cle donors. The two BMD cases showed a modest reduction (average reduction of 29%) of
dystrophin expression when BMD muscle sections were stained by anti-dystrophin ab15277
and dystrophin levels were compared to dystrophin mean expression in control sections.
Muscle samples of the two DMD patients stained with MANDYS106 had a reduction of 70%
of the mean dystrophin intensity in the control muscles. The two BMD muscle biopsies had
a reduction of the mean dystrophin intensity of 14% compared to the sections of the two
controls when the staining was performed using MANDYS106. Although there were no sig-
nificant differences between the mean dystrophin intensity in paediatric controls compared
to the BMD cases, the minimum values of the dynamic range of dystrophin detected in
DMD patients muscle is similar to the minimum values in BMD sections (Table 4). The
dynamic range of dystrophin mean intensity values of the control paediatric muscles is
broader than in BMD muscle sections (Table 4).
Discussion
The proof of concept for therapeutic approaches aimed to increase or induce dystrophin
expression are currently based on dystrophin quantification performed on muscle specimens.
Therefore, it is crucial to have an accurate and unbiased quantification method to monitor
dystrophin expression. Herein, we have developed a high throughput, operator-independent
technique to quantify dystrophin at the sarcolemma of all the myofibres present in a transverse
cryosection of human skeletal muscle. To identify a myofibre, we used either spectrin or lami-
nin staining to generate a “fibre mask” where subsequently dystrophin was quantified in each
individual fibre. Spectrin and laminin are present in two different muscle compartments: spec-
trin is associated with the cytoskeleton of the sarcolemma, whereas laminin is a component of
the extracellular membrane matrix of the basal lamina surrounding myofibres (Dubowitz V,
Sewry C, Oldfors A. Muscle biopsy: a practical approach. 4th ed. Elsevier-Saunders; 2013) [17].
Nevertheless, we did not find significant differences in the number of fibres identified using
either spectrin or laminin. Dystrophic muscle fibres may have interruptions at the sarcolemma
and it is possible that the number of myofibres identified by spectrin or laminin could differ
significantly. However, we found that in a typical DMD biopsy the number of fibres with sar-
colemmal damage identified by either spectrin or laminin staining is extremely small (less
than 1%). Therefore the fibre recognition step operated by either spectrin or laminin should
not affect the myofibre identification and subsequent dystrophin quantification.
The results obtained with this new technique are broadly similar and in keeping with the
Arechavala et al. method [12]. Nevertheless, this new method has considerable advantages
over the previous one because the high-throughput acquisition facilitates the analysis of large
numbers of fibres, giving a more accurate overall assessment of the dystrophin intensity in the
myofibre population within an entire muscle section. As it does not require involvement of the
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operator in the fibre selection, potential bias is removed. The potential for bias when assessing
dystrophin localisation had been recently raised by the FDA when reviewing the Sarepta
filing for Eteplirsen, an antisense designed to induce exon 51 skipping (https://www.fda.gov/
NewsEvents/Newsroom/PressAnnouncements/ucm521263.htm), so attempts to remove any
possible operator dependent bias are necessary.
Another advantage of this technique is that dystrophin is not normalised to spectrin. This is
important, as we show data (Fig 3a) indicating that spectrin levels are higher in DMD than in
control muscles. A similar finding has been previously published by Beekman and collabora-
tors who presented dystrophin data as absolute intensities, due to the higher spectrin levels
observed in DMD muscles compared to control muscles [16]. We also demonstrate that spec-
trin levels were higher in BMD than in control muscles, although this trend for increase did
not reach the statistical significance observed in DMD patients. Although the BMD samples
used in this study are from very mild patients (Table 1), with high levels of residual dystrophin
expression, we think it is important to highlight this finding. Importantly, these results suggest
that dystrophin intensity reported in previous pre-clinical work [18, 19] and in clinical trials
[13, 14] might have been underestimated, as in all these studies dystrophin intensity was nor-
malised to spectrin intensity. Similarly, the use of spectrin to normalise utrophin and beta dys-
troglycan in DMD muscle samples also needs to be interpreted with this consideration [20].
Depending on the anti-dystrophin antibody used, we found different mean intensity values.
Dystrophin antibody ab15277 gave slightly higher mean intensity than MANDYS106 in mus-
cle sections of DMD/BMD patients and paediatric controls (Figs 6 and 9). This is most likely
due to different affinities of the antibodies that has been observed in other studies [16]. Fur-
thermore, ab15277 and MANDYS106 recognize different portions of the dystrophin protein.
Nevertheless, using both dystrophin antibodies, we found statistically significant (p< 0.01)
variability in mean dystrophin intensity in sections cut from the same control muscle biopsy
but processed on different days. This is important as it provides an insight into the intrinsic
variability of immunolabelling experiments and acquisition settings (Fig 3a and 3b). This was
previously reported using different acquisition and analysis procedures [12, 15, 16]. There was
variability in the amount of dystrophin between fibres within the same muscle section in pae-
diatric controls as well as in DMD and BMD muscles (Figs 7c and 8c), as previously noticed by
previous authors [12] [16]. The dystrophin variability is most likely due to the fact that dystro-
phin expression is not uniform, even in the same muscle fibre fascicle, and this could be related
to the half-life of dystrophin transcript, dystrophin translation rate [10] and also epigenetic
control of dystrophin production regulated by miRNA [21]. Our method analyses a high per-
centage (99.8%) of myofibres within the muscle, enabling us to explore for the first time the
full range of dystrophin intensity variability. Our results suggest that each muscle is composed
of myofibres expressing different amounts of dystrophin at the sarcolemma. Dystrophin
expression has been relatively poorly studied in paediatric control muscles due to scarce avail-
ability of these samples. In a previous study performed by our group, we found no difference
in dystrophin average intensity in three muscle biopsies from adolescent control muscle
donors, but a fourth control muscle had significantly less dystrophin [12]. Data from another
study suggests that there is a difference in dystrophin intensity between different muscle
groups [16], but the numbers of muscles compared is too small to draw definite conclusions.
By using the Axio Scan/Definiens method, we found variability of mean dystrophin inten-
sity considering the entire myofibre population within the same muscle section in all seven
muscle blocks obtained from control donors. But interestingly, there was no statistically signif-
icant difference between the average dystrophin expression calculated from the seven muscle
blocks and the mean intensity value generated by each muscle block analysed. This is most
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likely related to the large number of fibres studied, that reduces any type of data dispersion
and makes average dystrophin levels homogenous in the muscles overall.
It should be noted that our method does not distinguish revertant fibres from fibres that
have restored dystrophin.
There is no immunocytochemistry technique using a single dystrophin antibody that allows
to recognize all revertant fibres, as different clusters of revertant fibres may express different
dystrophin epitopes [22, 23]. Although revertant fibres often have high levels of dystrophin,
they represent a very small percentage of the fibres in muscles of DMD patients and their num-
bers do not increase with time [23]. As the system we have developed allows the capture and
study thousands of muscle fibres in an unbiased way, the revertant fibres are unlikely to have a
significant effect on the amount of dystrophin within the entire muscle.
Another method to quantify dystrophin is Western blotting, that gives information on the
amount of dystrophin and its size, but gives no information on whether this dystrophin is cor-
rectly localized at the sarcolemma (rather than being, for example, cytoplasmic). In addition, it
gives no information on whether either a small proportion of fibres within a muscle has a large
amount of dystrophin, or many fibres contain moderate amounts of dystrophin (both such
muscles may have similar amounts of dystrophin on a blot). There is evidence from mouse
studies that, for functional improvement, relatively low levels of dystrophin are required, but
it must be uniformly expressed within a muscle [24] [19]. Our method allows the level of dys-
trophin in each fibre of a muscle biopsy to be determined and thus gives this vital biological
information. This, or very similar, methods will therefore be used as a secondary endpoint,
complementing Western blotting as the primary endpoint, in clinical trials designed to restore
dystrophin restoration.
In conclusion, we have developed a semi-automated and high throughput method for
acquiring an entire muscle section and quantifying dystrophin expression for each myofibre
within that section. We demonstrate that this method is robust and operator-independent,
due to the fully automated acquisition and Definiens algorithm analysis. We tested this new
technique on muscle sections of paediatric control, DMD and BMD patients and we showed
that the method was able to distinguish even small differences in dystrophin expression.
Furthermore, we demonstrated that each dystrophin distribution curve representing either
controls or DMD/BMD samples are composed by normally distributed data. Therefore, dys-
trophin is differentially expressed in the myofibre population within one muscle, underpin-
ning an inherent biological variability which we describe here for the first time. The basis and
consequences of this variablility are yet to be elucidated.
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